FDA issued its order in March this year after raising concerns over sterilisation of 15 batches, comprising 160,000 retail containers, of baby powder J&J produced in 2007, the shelf life of which ended in July 2010. The company has been held responsible for violation of the Drugs and Cosmetic Act, 1940 and the rules framed in 1945. FDA had expressed concerns over ethylene oxide used during sterilisation, which aimed to bring down microbial load. In view of the state government’s decision, J&J’s licence for cosmetic products stands cancelled and the company will have to close the manufacturing of these products at the plant.
However, the company will continue to make non-cosmetic products at the facility. The factory was making J&J Baby Powder, Band-Aid adhesive bandages and Stayfree sanitary napkins.
J&J’s appeal against FDA order was heard by the minister for food and drugs administration, Manohar Naik, on June 20. The order issued by the minister that day was reviewed by Business Standard.
“J&J has violated the section 18 of the Drugs & Cosmetic Act, 1940 and rule 142(c) of 1945 rules. The appeal stands rejected. FDA directives issued in this regard on March 30 are upheld. The licence stands cancelled from June 24,” the order said.
A J&J India spokesman said: “We appreciate that the Maharashtra state FDA has given us a hearing on the matter of our Mulund plant. However, we are deeply disappointed with the outcome. Nothing is more important to us than the safety of our products and the health of the consumers who use them.
He added: “We would like to reaffirm that we have been manufacturing Johnson’s Baby Powder at the Mulund plant for more than four decades with a strong record of safety, quality and regulatory compliance, and that product safety was not compromised at any point.”
We remain committed to providing India with safe, high quality products that help people care for themselves and their families.”
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)